FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4368361452> ?p ?o ?g. }

• W4368361452 endingPage "2914" @default.
• W4368361452 startingPage "2902" @default.
• W4368361452 abstract "This ongoing post-marketing surveillance monitors the long-term safety and effectiveness of vedolizumab in routine clinical practice in patients with moderate-to-severe ulcerative colitis (UC) in Japan. This interim analysis assessed induction-phase data, covering the initial three doses of vedolizumab. Patients were enrolled via a web-based electronic data capture system from approximately 250 institutions. Incidence of adverse events and treatment responses were assessed by the physicians after the patient had received three doses of vedolizumab or when the drug was discontinued, whichever occurred first. Therapeutic response was defined as any treatment response, including remission or improvement of complete or partial Mayo score, and was assessed in the total and stratified patient populations according to prior tumor necrosis factor alpha (TNFα) inhibitor treatments and/or baseline partial Mayo score. The total incidence of adverse drug reactions (ADRs) was 4.10% (11/268). Common ADRs were dizziness, nausea, and arthralgia, each reported in 0.75% of patients (2/268). Serious ADRs were herpes zoster oticus and UC, each reported in 0.37% of patients (1/268). Therapeutic response was reported in 84.5% (218/258) of all patients, 85.8% (127/148) of TNFα inhibitor-naïve patients, and 82.7% (91/110) of TNFα inhibitor-experienced patients. Among patients with partial Mayo score of ≥ 4 at baseline, partial Mayo score remission in patients without or with prior TNFα inhibitor treatment was 62.5% (60/96) and 45.6% (36/79), respectively. The results confirm a safety and effectiveness profile of vedolizumab consistent with that observed in previous trials. JapicCTI-194603, NCT03824561." @default.
• W4368361452 created "2023-05-05" @default.
• W4368361452 creator A5011183680 @default.
• W4368361452 creator A5020204603 @default.
• W4368361452 creator A5029088191 @default.
• W4368361452 creator A5037730409 @default.
• W4368361452 creator A5043553748 @default.
• W4368361452 creator A5044789630 @default.
• W4368361452 creator A5050542462 @default.
• W4368361452 creator A5057448803 @default.
• W4368361452 creator A5071194126 @default.
• W4368361452 creator A5071958820 @default.
• W4368361452 creator A5087765303 @default.
• W4368361452 date "2023-05-04" @default.
• W4368361452 modified "2023-10-14" @default.
• W4368361452 title "Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study" @default.
• W4368361452 cites W2031193040 @default.
• W4368361452 cites W2045506932 @default.
• W4368361452 cites W2162805528 @default.
• W4368361452 cites W2414026316 @default.
• W4368361452 cites W2525314273 @default.
• W4368361452 cites W2545034339 @default.
• W4368361452 cites W2551516232 @default.
• W4368361452 cites W2791923916 @default.
• W4368361452 cites W2804133062 @default.
• W4368361452 cites W2917617858 @default.
• W4368361452 cites W2919081348 @default.
• W4368361452 cites W2971037911 @default.
• W4368361452 cites W2972119029 @default.
• W4368361452 cites W2976731348 @default.
• W4368361452 cites W3178607042 @default.
• W4368361452 cites W4205389315 @default.
• W4368361452 cites W4211050664 @default.
• W4368361452 cites W4211138554 @default.
• W4368361452 doi "https://doi.org/10.1007/s12325-023-02500-6" @default.
• W4368361452 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37140705" @default.
• W4368361452 hasPublicationYear "2023" @default.
• W4368361452 type Work @default.
• W4368361452 citedByCount "0" @default.
• W4368361452 crossrefType "journal-article" @default.
• W4368361452 hasAuthorship W4368361452A5011183680 @default.
• W4368361452 hasAuthorship W4368361452A5020204603 @default.
• W4368361452 hasAuthorship W4368361452A5029088191 @default.
• W4368361452 hasAuthorship W4368361452A5037730409 @default.
• W4368361452 hasAuthorship W4368361452A5043553748 @default.
• W4368361452 hasAuthorship W4368361452A5044789630 @default.
• W4368361452 hasAuthorship W4368361452A5050542462 @default.
• W4368361452 hasAuthorship W4368361452A5057448803 @default.
• W4368361452 hasAuthorship W4368361452A5071194126 @default.
• W4368361452 hasAuthorship W4368361452A5071958820 @default.
• W4368361452 hasAuthorship W4368361452A5087765303 @default.
• W4368361452 hasBestOaLocation W43683614521 @default.
• W4368361452 hasConcept C120665830 @default.
• W4368361452 hasConcept C121332964 @default.
• W4368361452 hasConcept C126322002 @default.
• W4368361452 hasConcept C141071460 @default.
• W4368361452 hasConcept C197636746 @default.
• W4368361452 hasConcept C197934379 @default.
• W4368361452 hasConcept C2776207728 @default.
• W4368361452 hasConcept C2778715236 @default.
• W4368361452 hasConcept C2779134260 @default.
• W4368361452 hasConcept C2780479503 @default.
• W4368361452 hasConcept C535046627 @default.
• W4368361452 hasConcept C61511704 @default.
• W4368361452 hasConcept C61943457 @default.
• W4368361452 hasConcept C71924100 @default.
• W4368361452 hasConcept C90924648 @default.
• W4368361452 hasConceptScore W4368361452C120665830 @default.
• W4368361452 hasConceptScore W4368361452C121332964 @default.
• W4368361452 hasConceptScore W4368361452C126322002 @default.
• W4368361452 hasConceptScore W4368361452C141071460 @default.
• W4368361452 hasConceptScore W4368361452C197636746 @default.
• W4368361452 hasConceptScore W4368361452C197934379 @default.
• W4368361452 hasConceptScore W4368361452C2776207728 @default.
• W4368361452 hasConceptScore W4368361452C2778715236 @default.
• W4368361452 hasConceptScore W4368361452C2779134260 @default.
• W4368361452 hasConceptScore W4368361452C2780479503 @default.
• W4368361452 hasConceptScore W4368361452C535046627 @default.
• W4368361452 hasConceptScore W4368361452C61511704 @default.
• W4368361452 hasConceptScore W4368361452C61943457 @default.
• W4368361452 hasConceptScore W4368361452C71924100 @default.
• W4368361452 hasConceptScore W4368361452C90924648 @default.
• W4368361452 hasFunder F4320310465 @default.
• W4368361452 hasIssue "6" @default.
• W4368361452 hasLocation W43683614521 @default.
• W4368361452 hasLocation W43683614522 @default.
• W4368361452 hasLocation W43683614523 @default.
• W4368361452 hasOpenAccess W4368361452 @default.
• W4368361452 hasPrimaryLocation W43683614521 @default.
• W4368361452 hasRelatedWork W1994757005 @default.
• W4368361452 hasRelatedWork W2391106790 @default.
• W4368361452 hasRelatedWork W2587196664 @default.
• W4368361452 hasRelatedWork W2605674307 @default.
• W4368361452 hasRelatedWork W2611805711 @default.
• W4368361452 hasRelatedWork W2972119029 @default.
• W4368361452 hasRelatedWork W3035972576 @default.
• W4368361452 hasRelatedWork W4236316089 @default.
• W4368361452 hasRelatedWork W4311359465 @default.

• next